Metformin-A Thought-provoking Addition to Anticancer Therapies-Reply

JAMA Oncol. 2022 Feb 1;8(2):303-304. doi: 10.1001/jamaoncol.2021.6729.

Authors

Theodoros Tsakiridis¹, Gregory R Pond^{1

2}, James Wright^{1

2}

Affiliations

¹ Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
² Ontario Clinical Oncology Group, McMaster University, Hamilton, Ontario, Canada.

PMID: 34940805
DOI: 10.1001/jamaoncol.2021.6729

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Drug Resistance, Neoplasm
Humans
Metformin* / adverse effects

Substances

Metformin